Full-Time

Regional Sales Director

Mid Atlantic

Updated on 9/4/2026

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$184k - $245k/yr

+ Annual short-term incentive/bonus + Annual long-term incentive/equity

Washington, DC, USA + 1 more

More locations: Philadelphia, PA, USA

Remote

Remote within the Philadelphia or Washington, D.C. area; requires four full days in the field weekly and travel by car and airplane.

Bachelor's, Master's

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to Invivyd

See people who can refer or advise you

Requirements
  • A bachelor's degree from an accredited college or university is required.
  • A minimum of 10 years of experience in the biopharmaceutical, medical device, or healthcare industry is required.
  • At least 5 years of experience managing high-performing teams in the life sciences field is required.
  • A current, valid state driver's license and the ability to pass a motor vehicle record background check are required.
  • Experience with reimbursement, buy-and-bill, specialty pharmacies, integrated delivery networks, and federal channels is required.
  • The ability to work in the field four full days per week and travel by car and airplane as required is necessary.
  • Strong understanding and experience following laws, regulations, and industry codes governing interactions with healthcare professionals and healthcare organizations are required.
  • Strong understanding of the healthcare landscape and payer dynamics is required.
  • Strong leadership, coaching, and recruiting skills are required.
  • Strong presentation and communication skills are required.
  • The ability to adapt to evolving market conditions and drive continuous improvement is required.
  • The ability to foster engagement and ethical conduct is required.
Responsibilities
  • Lead and develop a high-performing team of Strategic Account Managers and Virology Care Specialists.
  • Promote company products responsibly to targeted healthcare providers and academic centers in alignment with company policies, standard operating procedures, laws, and guidelines.
  • Create a high-performance coaching culture that develops talent and drives results.
  • Set the vision for the region and lead the team through organizational transitions.
  • Execute sales strategies to achieve revenue and growth objectives while maintaining compliance with company policies and industry standards.
  • Engage with key accounts, build relationships, and partner with healthcare providers and academic centers to expand and retain business.
  • Coach in the field alongside Strategic Account Managers and Virology Care Specialists, providing feedback, skill development, and guidance on compliant selling behaviors.
  • Champion team growth and career development.
  • Act as a local liaison between the sales organization and other corporate functions, building consensus on area strategies and tactics.
  • Manage financial and field-staff resources to achieve objectives.
  • Establish and manage area expense budgets and ensure compliant return on investment.
  • Provide training, coaching, follow-up, and development to Strategic Account Managers throughout their work and career development.
  • Drive demand while aligning with long-term sales and profit objectives.
  • Drive team performance through team building, coaching, business planning, training, motivation, and management.
Desired Qualifications
  • A master's degree is preferred.
  • A proven record of leading a pharmaceutical sales team is strongly preferred.

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 PEMGARDA revenue reached $14.3 million, up 21% year over year.
  • Invivyd completed enrollment for DECLARATION and LIBERTY, with data expected late Q3 2026.
  • April 2026 sample-size re-estimation and June upsizing boosted statistical power and credibility.

What critics are saying

  • Invivyd disclosed substantial doubt about going concern in May 2026 without new financing.
  • Nasdaq warned on July 23, 2026 after IVVD stayed below $1.00 for 30 days.
  • If DECLARATION disappoints in Q3 2026, Invivyd loses its only near-term value driver.

What makes Invivyd unique

  • Invivyd owns fast-moving antibody engineering for immune-compromised viral prophylaxis, led by VYD2311.
  • DECLARATION’s upsized 2,400-patient design targets symptomatic COVID with BLA-enabling readout in Q3 2026.
  • Michael Mina joined as CMO, adding credibility in vaccine alternative and public-health positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.